Special Access for the Use of Voclosporin for Kidney Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01236287|
Recruitment Status : Available
First Posted : November 8, 2010
Last Update Posted : February 28, 2018
|Condition or disease||Intervention/treatment|
|Immunosuppression Transplantation, Kidney||Drug: Voclosporin|
Voclosporin is an investigational medication previously studied to prevent acute rejection in patients who receive a kidney transplant. This study is a compassionate release program where subjects previously participating in the study entitled A Phase 2B, Randomized, Multicenter, Open-Label, Concentration Controlled, Safety Study of ISA247 and Tacrolimus (Prograf®) in denovo Renal Transplant Patients (ISA05-01)" may be eligible to continue to receive voclosporin despite the Phase 2B study being terminated by the sponsor. Under the compassionate release program, subjects previously taking voclosporin may continue to receive the study medication until the drug is FDA-approved and commercially available in the United States.
Subjects will receive voclosporin and will be followed in an outpatient setting. After their initial visit, patients will return for follow-up at least every 3 months (through month 24) and then every 6 months (beginning at month 24). Safety and efficacy measurements will be taken at appropriate time points as outlined in the table below. Trough voclosporin measurements will be collected at least every 3 months (through month 24) and then every 6 months (beginning at month 24) or more frequently at clinic visits as appropriate (as indicated by clinical events (such as rejection, infection, adverse event) or concomitant administration of an interacting medication. Patient and graft survival data will be collected on an annual basis for safety reporting.
|Study Type :||Expanded Access|
|Official Title:||Special Access for the Use of Voclosporin for Kidney Transplantation|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01236287
|Contact: Meredith J Aull, Pharm.D.||(212) email@example.com|